Molecular Dissection of the Inhibitor Binding Pocket of Mitotic Kinesin Eg5 Reveals Mutants that Confer Resistance to Antimitotic Agents

Journal of Molecular Biology

Volumn 360, Issue 2, 2006, Pages 360-376

  Brier, Sébastien ^a   Lemaire, David ^a   DeBonis, Salvatore ^a   Forest, Eric ^a   Kozielski, Frank ^a  

^a INSTITUT DE BIOLOGIE STRUCTURALE   (France)

Author keywords

cancer; drug resistance; Eg5; mitotic kinesins; mutants

Indexed keywords

AMINO ACID; ANTIMITOTIC AGENT; KINESIN; LEUCINE; MONASTROL; MUTANT PROTEIN;

ARTICLE; BINDING SITE; DRUG BINDING; DRUG SPECIFICITY; ENZYME ACTIVITY; KINETICS; MASS SPECTROMETRY; MITOSIS; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL; WILD TYPE;

EID: 33745246040     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2006.04.062     Document Type: Article

References (48)

1. Blangy A., Lane H.A., d'Herin P., Harper M., Kress M., and Nigg E.A. Phosphorylation by p34cdc2 regulates spindle association of human Eg5, a kinesin-related motor essential for bipolar spindle formation in vivo. Cell 83 (1995) 1159-1169
2. Whitehead C.M., and Rattner J.B. Expanding the role of HsEg5 within the mitotic and post-mitotic phases of the cell cycle. J. Cell Sci. 111 (1998) 2551-2561
3. Cole D.G., Saxton W.M., Sheehan K.B., and Scholey J.M. A `slow` homotetrameric kinesin-related motor protein purified from Drosophila embryos. J. Biol. Chem. 269 (1994) 22913-22916
4. Kashina A.S., Baskin R.J., Wedaman K.P., Saxton W.M., and Scholey J.M. A bipolar kinesin. Nature 379 (1996) 270-272
5. Gordon D.M., and Roof D.M. The kinesin-related protein Kip 1p of Saccharomyces cerevisiae is bipolar. J. Biol. Chem. 274 (1999) 28779-28786
6. Kashina A.S., Rogers G.C., and Scholey J.M. The bimC family of kinesins: essential bipolar mitotic motors driving centrosome separation. Biochim. Biophys. Acta 1357 (1997) 257-271
7. Sharp D.J., Rogers G.C., and Scholey J.M. Microtubule motors in mitosis. Nature 407 (2000) 41-47
8. Kapitein L.C., Peterman E.J.G., Kwok B.H., Kim J.H., Kapoor T.M., and Schmidt C.F. The bipolar mitotic kinesin Eg5 moves on both microtubules that it crosslinks. Nature 435 (2005) 114-118
9. Wood K.W., Cornwell W.D., and Jackson J.R. Past and future of the mitotic spindle as an oncology target. Curr. Opin. Pharmacol. 1 (2001) 370-377
10. Miyamoto D.T., Perlman Z.E., Mitchison T.J., and Shirasu-Hiza M. Dynamics of the mitotic spindle-potential therapeutic targets. Prog. Cell Cycle Res. 5 (2003) 349-360
11. Bergnes G., Brejc K., and Belmont L. Mitotic kinesins: prospects for antimitotic drug discovery. Curr. Top. Med. Chem. 5 (2005) 127-145
12. Mayer T.U., Kapoor T.M., Haggarty S.J., King R.W., Schreiber S.L., and Mitchison T.J. Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science 286 (1999) 971-974
13. Kapoor T.M., Mayer T.U., Coughlin M.L., and Mitchison T.J. Probing spindle assembly mechanisms with monastrol, a small molecule inhibitor of the mitotic kinesin. J. Cell Biol. 150 (2000) 975-988
14. Haggarty S.J., Mayer T.U., Miyamoto D.T., Fathi R., King R.W., Mitchison T.J., et al. Dissecting cellular processes using small molecules: identification of colchicine-like, taxol-like and other small molecules that perturb mitosis. Chem. Biol. 7 (2000) 275-286
15. Nakazawa J., Yajima J., Usui T., Ueki M., Takatsuki A., Imoto M., et al. A novel action of terpendole E on the motor activity of mitotic kinesin Eg5. Chem. Biol. 10 (2003) 131-137
16. Sakowicz R., Finer J.T., Beraud C., Crompton A., Lewis E., Fritsch A., et al. Antitumor activity of a kinesin inhibitor. Cancer Res. 64 (2004) 3276-3280
17. Hota S., Yarrow J.C., Yang J.G., Garrett S., Renduchintala K.V., Mayer T.U., and Kapoor T.M. HR22C16: a potent small-molecule probe for the dynamics of cell division. Angew. Chem. Int. Ed. 42 (2005) 2379-2382
18. Marcus A.I., Thomas S.L., Garrett S., Zelnak A., Kapoor T., and Giannakakou P. Mitotic kinesin inhibitors induce mitotic arrest and cell death in taxol-resistant and -sensitive cancer cells. J. Biol. Chem. 280 (2005) 11569-11577
19. DeBonis S., Skoufias D.A., Lebeau L., Robin G., Margolis R., Wade R.H., and Kozielski F. In vitro screening for inhibitors of the human mitotic kinesin, Eg5, with antimitotic and antitumor activity. Mol. Cancer Ther. 3 (2004) 1079-1090
20. Cox C.D., Breslin M.J., Mariano B.J., Coleman P.J., Buser C.A., Walsh E.S., et al. Kinesin spindle protein (KSP) inhibitors. Part 1: the discovery of 3,5-diaryl-4,5-dihydropyrazoles as potent and selective inhibitors of the mitotic kinesin KSP. Bioorg. Med. Chem. Letters 15 (2005) 2041-2045
21. Gartner M., Sunder-Plassmann N., Seiler J., Utz M., Vernos I., Surrey T., and Giannis A. Development and biological evaluation of potent and specific inhibitors of mitotic kinesin Eg5. ChemBioChem 6 (2005) 1-6
22. DeBonis S., Simorre J.P., Crevel I., Lebeau L., Skoufias D.A., Blangy A., et al. Interaction of the mitotic inhibitor monastrol with human kinesin Eg5. Biochemistry 42 (2003) 338-349
23. Yan Y., Sardana V., Xu B., Homnick C., Halczenko W., Buser C.A., et al. Inhibition of a mitotic motor protein: where, how, and conformational consequences. J. Mol. Biol. 335 (2004) 547-554
24. Luo L., Carson J.D., Dhana D., Jackson J.R., Huang P.S., Lee Y., et al. Mechanism of inhibition of human KSP by monastrol: insights from kinetic analysis and the effect of ionic strength on KSP inhibition. Biochemistry 43 (2004) 15258-15266
25. Crevel I.M., Alonso M.C., and Cross R.A. Monastrol stabilises an attached low-friction mode of Eg5. Curr. Biol. 14 (2004) R411-R412
26. Cochran J.C., Gatial III J.E., Kapoor T.M., and Gilbert S.P. Monastrol inhibition of the mitotic kinesin Eg5. J. Biol. Chem. 280 (2005) 12658-12667
27. Rosenfeld S.S., Xing J., Jefferson G.M., and King P.H. Docking and rolling, a model of how the motor Eg5 works. J. Biol. Chem. 280 (2005) 35684-35695
28. Leizerman I., Avunie-Masala R., Elkabets M., Fich A., and Gheber L. Differential effects of monastrol in two human cell lines. Cell Mol. Life Sci. 61 (2004) 2060-2070
29. Skoufias, D.A., DeBonis, S., Saoudi, Y., Lebeau, L., Crevel, I., Cross R., et al. S-trityl-L-cysteine is a reversible, tight-binding inhibitor of the human kinesin motor Eg5 that specifically blocks mitotic progression. J. Biol. Chem. in the press.
30. Brier S., Lemaire D., Debonis S., Forest E., and Kozielski F. Identification of the protein binding region of S-trityl-L-cysteine, a new potent inhibitor of the mitotic kinesin Eg5. Biochemistry 43 (2004) 13072-13082
31. Englander J.J., Rogero J.R., and Englander S.W. Protein hydrogen exchange studied by the fragment separation method. Anal. Biochem. 147 (1985) 234-244
32. Dharmasiri K., and Smith D.L. Mass spectrometric determination of isotopic exchange rates of amide hydrogens located on the surfaces of proteins. Anal. Chem. 68 (1996) 2340-2344
33. Garcia R.A., Pantazatos D., and Villarreal F.J. Hydrogen/deuterium exchange mass spectrometry for investigating protein-ligand interactions. Assay Drug Dev. Technol. 2 (2004) 81-91
34. Williams J.W., and Morrison J.F. The kinetics of reversible tight-binding inhibition. Methods Enzymol. 63 (1979) 437-467
35. Copeland R.A. Enzymes 2nd edit. A Practical Introduction to Structure, Mechanism, and Data Analysis (2000), Wiley-VCH, New York 305-317
36. Szedlacsek S.E., and Duggleby R.G. Kinetics of slow and tight-binding inhibitors. Methods Enzymol. 249 (1995) 144-180
37. Jackson J.R., Auger K.R., Gilmartin A., Eng W.K., Luo L., Concha N., et al. A resistance mechanism for the KSP inhibitor Ispinesib implicates point mutations in the compound binding site. Poster Meeting C207, AACR-NCI-EORTC International Conference on Molecular Target in Cancer Therapeutics: Discovery, Biology and Clinical Applications, November 14-18, Philadelphia (2005)
38. Turner J., Anderson R., Guo J., Beraud C., Fletterick R., and Sakowicz R. Crystal structure of the mitotic spindle kinesin Eg5 reveals a novel conformation of the neck-linker. J. Biol. Chem. 276 (2001) 25496-25502
39. Maliga Z., Xing J., Cheung H., Juszczak L.J., Friedmann J.M., and Rosenfeld S.S. A pathway of structural changes peoduced by monastrol binding to Eg5. J. Biol. Chem. 281 (2006) 7977-7982
40. Brier S., Lemaire D., DeBonis S., Kozielski F., and Forest E. Use of hydrogen/deuterium exchange mass spectrometry and mutagenesis as a tool to identify the binding region of inhibitors targeting the human mitotic kinesin Eg5. Rapid Commun. Mass Spectrom. 20 (2006) 456-462
41. Jordan M.A., and Wilson L. Microtubules as a target for anticancer drugs. Nature Rev. Cancer 4 (2004) 253-265
42. Orr G.A., Verdier-Pinard P., McDaid H., and Horwitz S.B. Mechanisms of taxol resistance related to microtubules. Oncogene 22 (2003) 7280-7295
43. Hackney D.D., and Jiang W. Assays for kinesin microtubule-stimulated ATPase activity. Methods Mol. Biol. 164 (2001) 65-71
44. Funk C.J., Davis A.S., Hopkins J.A., and Middleton K.M. Development of high-throughput screens for discovery of kinesin adenosine triphosphatase modulators. Anal. Biochem. 329 (2004) 68-76
45. Segel I.H. Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady-state Enzyme Systems (1975), Wiley-Interscience Publication 100-159
46. Morrison J.F. Kinetics of the reversible inhibition of enzyme-catalysed reactions by tight-binding inhibitors. Biochim. Biophys. Acta 185 (1969) 269-289
47. Cha S. Tight-binding inhibitor-kinetic behavior. Biochem. Pharmacol. 24 (1975) 2177-2185
48. DeLano W.L. The PyMOL Molecular Graphics System (2002), DeLano Scientific, San Carlos, CA, USA